Penyagolosa Trail Saludable 2025
Launched by UNIVERSITAT JAUME I · May 5, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Penyagolosa Trail Saludable 2025 clinical trial is studying the experiences of athletes who take part in Ultratrail races, which are long-distance running events that can be quite challenging. The researchers want to learn more about how these runners train, how their bodies perform on different types of terrain, and what factors might predict how well they do in the race. They are also interested in understanding any differences between male and female runners in terms of their physical responses during the race.
To participate in this study, you need to be a healthy adult aged 18 to 60 who has completed at least two races that are 65 kilometers or longer. You also need to be registered for the CSP 2025 race. However, individuals with heart or kidney diseases, or those taking ongoing medications, will not be eligible to join. If you decide to participate, you can expect to help researchers gather important information about Ultratrail running that could benefit future athletes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults healthy with 18-60 years
- • Must have completed at least two races of 65 km or longer.
- • Must be registered as a participant in the CSP 2025 race
- Exclusion Criteria:
- • Having heart disease
- • Having kidney disease
- • Taking a medication on an ongoing basis
About Universitat Jaume I
Universitat Jaume I (UJI) is a leading academic institution located in Spain, dedicated to advancing knowledge and innovation through research and education. With a strong emphasis on interdisciplinary collaboration, UJI conducts clinical trials aimed at addressing pressing health challenges and improving patient outcomes. The university's commitment to ethical standards and rigorous scientific methodologies ensures the integrity and reliability of its research endeavors. By fostering partnerships with healthcare professionals and industry stakeholders, UJI aims to translate research findings into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Castellón De La Plana, Castellón, Spain
Castellón De La Plana, , Spain
Patients applied
Trial Officials
Carlos Hernando
Principal Investigator
Universitat Jaume I
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported